Truist Securities Maintains Buy on Palvella Therapeutics, Raises Price Target to $190

Benzinga · 1d ago
Truist Securities analyst Danielle Brill maintains Palvella Therapeutics (NASDAQ:PVLA) with a Buy and raises the price target from $105 to $190.